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  Hip dysplasia (HD) is one of the most important bone and 
joint diseases in dogs. Making the radiographic diagnosis is 
s o m e t i m e  p o s s i b l e  w h e n  t h e  d i s e a s e  h a s  m a r k e d l y  
progressed. Chondroitin sulfate (CS) and hyaluronan (HA) 
are  the  most  important  cartilage  biomolecules  that  are 
elevated in the serum taken from dogs with osteoarthritis. 
The  serum  CS  and  HA  can  be  detected  by  an  ELISA 
technique,  with  using  monoclonal  antibodies  against  CS 
epitope 3B3 and WF6 and the HA chain as the primary 
antibodies. The aim of this study was to compare the levels 
of serum CS (both epitopes) and HA in non-HD and HD 
dogs.  All  123  dogs  were  categorized  into  2  groups.  The 
non-HD group was composed of 98 healthy dogs, while the 
HD group was comprised of 25 HD dogs. Blood samples 
were collected for analyzing the serum CS and HA levels 
with using the ELISA technique. The results showed that 
the average serum level of the CS epitope WF6 in the HD 
group  (2,594  ±  3,036.10  ng/ml)  was  significantly  higher 
than that in the non-HD group (465 ±  208.97 ng/ml) (p ＜ 
0.01) while the epitope 3B3 in the HD group (105 ±  100.05 
n g / m l )  w a s  s i g n i f i c a n t l y  l o w e r  t h a n  t h a t  i n  t h e  n o n - H D  
group (136 ± 142.03 ng/ml) (p ＜ 0.05). The amount of serum 
HA in the HD group (134.74 ± 59.71 ng/ml) was lower than 
that in the non HD group (245.45 ± 97.84 ng/ml) (p ＜ 0.05). 
The results indicate that the serum CS and HA levels might 
be used as biomarkers for osteoarthritis in HD dogs. 
Keywords: biomarker, chondroitin sulfate, dog, hip dysplasia, 
osteoarthritis
Introduction 
    Many studies have been done to understand the 
mechanism of cartilage degradation in joint disease and to 
assess changes in the cartilage metabolism in vivo. In vitro 
studies have enormously increased our understanding of 
how cytokines or growth factors influence cartilage 
metabolism, but it is obviously important to develop the 
means of studying and understanding cartilage metabolism 
in vivo to determine how the cartilage metabolism changes 
in a disease state. Moreover, an in vivo approach may also 
help us determine whether therapeutic interventions have 
beneficial or negative effects on cartilage metabolism. 
  Articular cartilage is a metabolically-active structure that 
is specifically designed to accommodate the tensile and 
compressive forces generated within the joint. This 
cartilage is composed of cells named chondrocytes, and 
these cells produce the extracellular matrix (ECM). The 
biochemical properties of cartilage and the physical 
function of joints are critically dependent on the integrity 
of the matrix. The ECM molecules in cartilage include 
proteoglycan (PG), hyaluronan (HA), glycoprotein and 
type II collagen. Proteoglycans are a family of glycocon-
jugates with a central core protein to which one or more 
glycosaminoglycan (GAG) side chains are covalently 
linked post-translationally [62]. In addition, most of the 
PGs exist as aggregates that are formed by the non- 
covalent association of proteoglycan with HA and linked 
protein [22]. Among the PGs in cartilage, the most crucial 
for the proper functioning of articular cartilage is aggrecan, 
which is one of the large aggregating chondroitin sulfates 
(CSs) [28]. CS consists of an alternating sequence of 
D-glucoronate and N-acetyl-D-galactosamine-4/6-sulfate 
residues that are linked through alternating bonds [56]. 
Although the CSs are often referred to as if they were a 
homogenous substance, their polysaccharide chains are 
comprised of several unique, but structurally similar 
disaccharides; the most abundant are CSs, which are 
typically chondroitin-4-sulfate and chondroitin-6-sulfate. 
The CS is a heterogenous group of compounds that have 
different molecular masses (15,000-25,000 kDa) and 
electric change densities [27], and CSs are an essential 318    Korakot Nganvongpanit et al.
component of the connective tissue ECM, including the 
hyaline cartilage, and the CSs provide elasticity and other 
functions. 
  The HA is a ubiquitous component of the ECM of most 
animal tissues. A high molecular weight (300-2,000 kDa) 
member of the polysaccharides group is termed GAG [39]. 
HA is a linear macromolecule that is composed of a repeating 
disaccharide units: β-1,4-glucuronic acid-β-1,3-N-acetyl- 
D-glucosamine [16]. HA is mainly produced by fibroblasts 
and other specialized connective tissue cells. Although HA 
is widely distributed throughout the body (umbilical cord, 
nasal cartilage, vitreum, cutis or lymph of the thorax), the 
highest concentration is found in synovial fluid and also 
connective tissue such as the synovial membrane [31]. Its 
production has been linked to a variety of diseases [30].
  Hip dysplasia (HD) is the abnormal development of the 
coxofemoral joint [38]. The disorder has been reported in 
humans and most domestic animals. The first report of HD 
in dogs was published in 1935. This disorder has become 
one of the most commonly diagnosed orthopedic diseases 
in dogs [25]. A study in 2003 showed that the prevalence of 
HD was 19.3% in the general population of pet dogs. The 
percentage of dysplasia for these breeds in that study was 
35.4% for Rottweilers, 32.9% for German Shepherds, 
30.3% for Golden Retrievers and 27% for Labrador 
Retrievers [53]. Moreover, the majority of the HD dogs 
(80%) had osteoarthritis (OA) [59]. So far, the initiating 
factors are unknown, and the rate and extent of the 
development of HD disease are variable, but the risk 
factors are both genetic [33] and environmental [11]. As 
mentioned above, most of the dogs with HD in the above 
mentioned study also had OA, but the standardized 
diagnostic protocol consists of the clinical sign, a physical 
examination and evaluation of the radiographic results, 
which can not detect OA in its early stages [42,45]. 
Moreover, many factors influence the radiographic 
diagnosis, such as the dog’s position during X-ray, the 
beam direction, the film quality, the development process 
or the severity of the disease [45] and most cases require 
contrast medium for making the final diagnosis [1]. 
  The OA is defined as a non-inflammatory, degenerative 
joint disease that’s characterized by the loss of articular 
cartilage, subchondral osteosclerosis and marginal 
hypertrophy of bone; this is accompanied with pain and 
soft tissues stiffness that’s aggravated by prolonged 
activity [41]. The collagen framework becomes disrupted, 
and the PG content of the articular cartilage diminishes, 
particularly near the articular surface. PG fragments that 
contain CS and keratin sulfate (KS), as well as the 
breakdown products of type II collagen, are liberated in 
increased concentrations to reach the synovial fluid and 
ultimately the serum [5,21,34].
  Biomarkers have been widely used to monitor disease 
activity, to predict disease progression and to study the 
effects of novel therapeutic interventions in a variety of 
joint diseases [9,10,36,37,40,48,61]. Biomarkers have also 
been used in a variety of species such as dogs [10,21, 
51,52], horses [17,44,47], mice [19] and rabbits [29]. Most 
of the biomarkers used in joint disease are the articular 
cartilage components such as CS [5,10,13], KS [5], HA 
[6,10,19,34] or collagen type II [23]. It is well recognized 
that the early stages of cartilage degradation and 
osteoarthritis are difficult or impossible to define 
diagnostically. In normal cartilage metabolism, the balance 
between catabolism and anabolism is necessary for 
maintenance of the cartilage’s function [12]. This 
metabolism changes when the joint environment is 
interrupted by factors such as chemical or physical effects. 
The biomolecules are upregulated via synthesis from the 
chondrocytes to restore the balance between catabolism 
and anabolism in the initial phase. For this process, many 
biomarkers such as matrix metalloprotease-3 or tissue 
inhibitor of metalloprotease-1 [21] and CS epitope 3B3 [43] 
were found to be at higher concentrations. In this disease 
state, the articular cartilage is highly degraded, and the joint 
develops OA if the balance is not recovered in the last phase 
[48,54]. Some biomolecules were elevated in this phase: 
KS [51] and CS epitope WF6 [43]. Those biomarkers are 
first released into the synovial fluid and then into the blood 
stream via the lymph system [63]. In the studies concerned 
with joint clearance, a considerable amount of the labeled 
radioactive GAG that was injected into the joint cavity was 
released into the blood within a few hours [3]. Thus, the 
determination of those bio- molecular levels in the serum 
may allow assessment of the joint tissue metabolism. 
Regarding the GAG levels in OA, it was noted that horses 
with OA showed high GAG levels in the synovial fluid as 
well as in the serum [2]. The advantage of serum 
measurement is the ease of collecting the sample, and 
especially in small animals such as dogs or cats. 
  The diagnosis of OA is generally based on the clinical and 
radiographic changes that occur in the later stages of the 
disease. In the present study, we sought to investigate 
aggrecan (CS epitope 3B3 and WF6) and HA metabolism 
in HD dogs. We report here on the use of CS (3B3 epitope 
and WF6) and HA as biomarkers for OA in HD dogs. A 
novel monoclonal antibody (WF6), which recognizes a 
native epitope in CS chains, was evaluated together with 
using a monoclonal antibody 3B3, which recognizes 
unsaturated terminal chondroitin 6-sulfate after 
chondroitinase ABC digestion [13,15,49]. 
Materials and Methods
Animals
  One hundred and twenty three native Thai dogs, 2-5 years 
old, were categorized into 2 groups. Ninety eight dogs 
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They were 43.9 ± 11.2 months old and their body weight 
were 16.8 ± 6.1 kg. The other group had 25 dogs which was 
HD group consisting of 15 male and 10 female. They were 
45.8 ± 10.2 months old and their weight were 17.8 ± 7.2 kg. 
The relationship between body weight and the serum 
biomarker was examined by dividing, the non-HD group 
into 5 subgroups according to their body weight: group 1 
(less than 10 kg, n = 15), group 2 (from 10 kg to less than 
15 kg, n = 30), group 3 (from 15 kg to less than 20 kg, n = 
28), group 4 (from 20 kg to less than 25 kg, n = 15) and 
group 5 (greater than or equal to 25 kg, n = 10), respectively. 
However, HD group did not divide into subgroups and 
investigate the relationship between gender, weight and 
serum biomarker. Because of the biomarkers in all animals 
were changed according to the progress of disease. 
  All the animals had their age and weight recorded. In the 
non-HD group, 98 non-HD dogs were diagnosed based on 
signalments, physical examination and gait analysis [48], 
and they were radiographed using the standard position 
[15]; the phenotypic evaluation of the hips was done 
according to the Orthopedic Foundation for Animals 
(USA), in which the animals fall into seven different 
categories. Those categories are normal (excellent, good, 
fair), borderline, and dysplastic (mild, moderate, severe). 
The HD group consisted of 25 HD dogs that were 
diagnosed according to their clinical signs. Radiography 
was used for the final diagnosis. Briefly, for the 
radiographic evaluation, the dogs underwent radiographic 
examinations, and a ventrodorsal projection of the 
coxofemoral joints was retrieved. Evaluation for the 
proper radiographic technique was conducted. The 
diagnostic studies we considered were those in which the 
entire well-positioned pelvis was included. For these 
diagnostic studies, the obturator foramina were symmetri-
cal and the femora were positioned to allow for accurate 
assessment of the femoral head and neck area. All the dogs 
in the HD group were classified as the severe grade. 
Briefly, for the radiographic findings of moderate to severe 
grade HD, there is significant subluxation present, where 
the femoral head is barely seated into the shallow socket, 
and this causes joint incongruence. There are secondary 
arthritic bone changes, usually along the femoral neck and 
head (termed remodeling), acetabular rim changes (termed 
osteophytes or bone spurs) and various degrees of 
trabecular bone pattern changes, and this is called 
sclerosis. For a severe grade of HD, there is significant 
subluxation present, where the femoral head is partly or 
completely dislocated from the shallow socket. There are 
also large amounts of secondary arthritic bone changes 
along the femoral neck and head, acetabular rim changes 
and large amounts of abnormal bone pattern changes. 
Blood collection
    Ten milliliter blood samples were collected from the 
cephalic vein of each dog. All the blood samples were 
taken in the morning before feeding the dogs. Two 
milliliters of the blood samples from each dog were kept in 
anticoagulant (100 IU/ml heprin; APS Finechem, Australia) 
for the complete blood count (CBC). Eight milliliters of the 
blood samples were centrifuged at 10,000 × g for 15 min to 
obtain the serum and this was kept frozen at -20
oC until 
blood chemical tests and biomarker assay were performed.
Hematology and biochemistry
  The biochemical analyses, CBCs and blood chemistry 
tests were conducted at the Small Animal Hospital, Faculty 
of Veterinary Medicine, Chiang Mai University, Chiang 
Mai, Thailand. The blood samples were analyzed for the 
CBC, including the hematocrit, the haemoglobin level, the 
red blood cell count and white blood cell count (WBC) and 
the platelet count. Two milliliters of serum were analyzed 
for blood chemicals, including aspartate aminotransferase, 
alanine aminotranferase, blood urea nitrogen and creati-
nine. 
Biomarker assay
  The biomarker assay that uses ELISA follows a previous 
study that was done by our research group [46,49,50]. Prior 
to performing competitive immunoassay with monoclonal 
antibody 3B3 (Seikagaku, Japan), the samples (175 μl of 
serum) were digested with using chondroitinase ABC 
(Sigma-Aldrich, USA) [an equal volume of 0.1 U/ml (in 
chondroitinase ABC buffer: 0.1 M sodium acetate, 1.0 M 
Tris-HCl, pH 7.3)]; they were incubated at 37
oC overnight, 
followed by heating at 100
oC for 10 min. The digested 
samples were spun in a microcentrifuge for 10 min to 
remove any precipitated protein and the supernatants were 
then collected and analysed.
ELISA-based assay for the chondroitin sulfate 3B3 
epitope
  The quantitative ELISA for the epitopes recognized by 
monoclonal antibody 3B3 was modified from an assay that 
was originally developed for synovial fluid [20]. The 
samples from the chondroitinase ABC-digested human 
serum were diluted in TE buffer (0.1 M Tris HCl (pH 7.4), 
0.15 M sodium chloride, 0.1% Tween 20 and 0.1% BSA) 
and the samples were then were mixed with an equal 
volume of monoclonal antibody 3B3 (from ascites fluid, 
diluted 1：10,000 in TE buffer) in 1.5 ml plastic tubes; 
they were then incubated at 37
oC for 1 h. The samples were 
added to microplate wells that were previously coated with 
porcine laryngeal aggrecan core protein (100 μl/well: 77 
ng/ml), and they were blocked with 1% BSA and then 
incubated at 37
oC for a further 1 h. The wells were washed 
3 times with TE buffer, and peroxidase conjugated 
anti-mouse IgM antibody (Sigma-Aldrich, USA) was 
added (100 μl/well of a 1：1,000 dilution in TE buffer) and 320    Korakot Nganvongpanit et al.
then the samples were allowed to incubate at 37
oC for a 
further 1 h. The bound peroxidase was detected by adding 
o-PD substrate (100 μl/well in citrate buffer, pH 5.0). The 
reaction was stopped with adding 50 μl/well of 4 M 
sulfuric acid and the absorbance was determined using a 
microplate reader at a dual wavelength of 492/690 nm. 
Measurement of the absorbance ratio at the two 
wavelengths reduced any well-to-well difference of 
non-specific interference, which can cause absorption at 
both wavelengths. The standard used was porcine 
aggrecan core protein (chondroitinase ABC-digested 
porcine laryngeal cartilage aggrecan) at various 
concentrations (4-2,000 ng/ml) The concentration of the 
3B3(+) epitope in the supernatant samples was calculated 
from the standard curve.
ELISA-based assay for the chondroitin sulfate WF6 
epitope
  A quantitative 2-step ELISA was developed based on the 
results from an initial study that characterised the epitopes 
recognized by monoclonal antibody WF6 [60]. Diluted 
human serum samples (1：5 in 6% BSA-TE buffer) were 
added to 1.5 ml plastic tubes that contained an equal 
volume of monoclonal antibody WF6 (cell culture 
supernatant, 1：200 dilution in the TE buffer). The 
standard we used was embryonic shark skeletal cartilage 
aggrecan (the A1D1 fraction) at different concentrations 
(19-10,000 ng/ml) of 6% BSA in the TE buffer. After 
incubation at 37
oC for 1 h, the samples (or standard) mixed 
with WF6 were added to the microtitre plate, which was 
previously coated with shark skeletal aggrecan (the A1 
fraction) (100 μl/well: 10 ug/ml), and the samples were 
blocked with 1% BSA. The plates were incubated at 37
oC 
for 1 h and the wells were then washed with the TE buffer; 
peroxidase conjugated anti-mouse IgM antibody (Sigma- 
Aldrich, USA) was then added (100 ml/well; 1：2,000 
dilution in the TE buffer). After incubation at 37
oC for a 
further 1 h, the amount of bound peroxidase was 
determined with using o-PD substrate (Sigma-Aldrich, 
USA) and the plates were read at 492/690 nm, as was 
described above. The concentration of the epitope WF6 in 
the samples was calculated from the standard curve.
ELISA-based assay for hyaluronan
  An ELISA was developed for performing hyaluronan 
assay in serum, and this was based on previous work with 
HA binding proteins [32]. Human serum samples or 
standard HA (Healon; Pharmacia Pharmaceutical AB, 
Sweden) at various concentrations (19-10,000 ng/ml in 6% 
BSA-PBS pH 7.4) were mixed with an equal volume of 
bovine articular cartilage-biotinylated HABPs (1：200 in 
0.05 M Tris- HCl buffer, pH 8.6). After incubation at room 
temperature for 1 h, the samples (100 μl) were added to 
microplate wells, which were previously coated with 
human umbilical cord HA (Sigma-Aldrich, USA) (100 
μl/well of 10 μg/ml); they were then blocked with 1% BSA 
(150 μl/well). After further incubation at room temperature 
for 1 h, the wells were washed with PBS-Tween buffer, and 
peroxidase conjugated anti-biotin antibody (Zymed, USA) 
(1：2,000 dilution, 100 μl/well in PBS) was added next. 
The plate was incubated at room temperature for a further 
1 h and the bound peroxidase was determined with using 
o-PD substrate. The plates were read at 492/690 nm, as was 
described above. The amount of HA in the samples was 
calculated from the standard curve.
Statistical analysis
  The CS and HA data from the serum are reported as means 
± SD. The non-parametric 2-sample Mann-Whitney 
procedure was used to test for differences between the 
non-HD and HD groups. Paired t-tests were performed to 
test the (one-tailed hypothesis that 1) the biomarker levels 
(CS and HA) depended on the dogs’ weights in the non-HD 
group and 2) the biomarker levels in the males were 
different from that in the females. The relative data was 
analyzed using the Statistical Analysis System version 8.0 
(SAS Institute, USA) software package. p values less than 
0.05 were considered to be significant.
Results
Hematology and biochemistry
  Table 1 shows the mean values for non-HD and HD 
group. Most of the values were not significantly different 
between the non-HD and HD group (p ＞ 0.05). The WBC 
in the HD group was increased when compared to that of 
the non-HD groups (p ＜ 0.05). This increase came from 
the total number of neutrophils, which was significantly 
higher in the HD group (p ＜ 0.05), while the other cell 
numbers (lymphocytes, monocytes, eosinophils and 
basophils) were not different between the groups (p ＞ 
0.05). 
The level of serum CS (epitope WF6 and 3B3) and 
HA in the serum 
  All the dogs in the HD group were diagnosed as having 
hip dysplatic, but they were not categorized into different 
pathological stages (mild, moderate, severe). The level of 
CS epitope 3B3 in the HD group (105 ± 100.05 ng/ml) was 
significantly (p ＜ 0.05) lower than that in the non-HD 
group (136 ± 142.03 ng/ml). Yet the level of CS epitope 
WF6 in the HD group (2,594 ± 3,036.10 ng/ml) was 
significantly (p ＜ 0.01) higher than that in the non-HD 
group (465 ± 208.97 ng/ml). The level of HA in the HD 
group (134.74 ± 59.71 ng/ml) was lower than that in the 
non-HD group (245.45 ± 97.84 ng/ml) (p ＜ 0.05), as is 
shown in Fig. 1. Biomarkers for osteoarthritis in canine hip dysplasia    321
Table 1. Comparison of complete blood counts and blood chemistry between the non-hip dysplasia (HD) and HD groups
Normal range
† HD group Non-HD group p-value
‡
Hematocrit (%) 22.5-57.5 36.82 ± 4.25 32.76 ± 2.25 0.1554
Hemoglobin (g/dl)   7.7-20.6 16.44 ± 2.98 15.15 ± 3.54 0.4436
WBC count (cell/μl)   6,000-33,700   27,947 ± 932.23   20,190 ± 591.61   0.0145*
Neutrophil (%)   0-78   49.44 ± 12.01 41.83 ± 8.38 0.0381
Lymphocyte (%) 19-76 40.06 ± 9.65   43.11 ± 10.95 0.4587
Monocyte (%)   0-33   5.30 ± 1.20   8.06 ± 1.43 0.0588
Eosinophil (%)   1-40   4.30 ± 1.18   6.33 ± 1.94 0.1757
Basophil (%) 0-1   0.80 ± 0.21   0.67 ± 0.12 0.4493
AST (U/l)   13-131   74.10 ± 21.02   70.67 ± 15.21 0.7635
ALT (U/l)     1-150     78.8 ± 18.73   87.94 ± 20.41 0.4736
BUN (mg/dl)   3-41 21.90 ± 7.94 25.81 ± 8.69 0.2941
Creatinine (mg/dl) 0.18-2.76   1.00 ± 0.56   0.92 ± 0.22 0.5676
*The significant difference (p ＜ 0.05) between the non-HD and HD groups. 
†Cited from Kaewsakorn et al. [26]. 
‡The p-values between the
HD and non-HD groups. AST: aspartate aminotransferase, ALT: alanine aminotranferase, BUN: blood urea nitrogen. Data are expressed as
mean ± SD.
Fig. 1. The levels of serum chondroitin sulfate epitope 3B3 (A) and WF6 (B) and hyaluronan (C) in the non-hip dysplasia (HD) group
compared to the HD group. Data show the mean ± SD. *The significant difference (p ＜ 0.05) between the non-HD and HD groups. 
The relationship between gender, body weight and 
serum biomarker levels in the non-HD group
    The average body weight in each subgroup was 
significantly different (p ＜ 0.05, data not shown). Most of 
the HD dogs (44%) were 20-25 kg for their body weight, 
and none were less than 10 kg. The level of all the 
biomarkers in the different weight subgroups was not 
significantly different (p ＞ 0.05) among the 5 subgroups 
(Fig. 2). Moreover, those biomarker levels were also not 
significantly different (p ＞ 0.05) between the male and 
female dogs (Fig. 3). 
Discussion
  The present study showed that HD dogs have the highest 
level of serum CS epitopes WF6, which means the 
cartilage in the HD joint was degraded and it developed 
into OA. We found the level of CS epitope WF6 in the HD 
group to be 150% higher, while epitope 3B3 in the HD 
group was 30% lower than that of the non-HD group. In 
agreement with the review by Nganvongpanit and 
Ong-Chai [43] the levels of those biomarkers in chronic 
OA changed in the same way. The study that was done by 
Peansukmanee et al. [47] found that the level of CS epitope 
WF6 was higher in OA horses, but the CS epitope 3B3 was 322    Korakot Nganvongpanit et al.
Fig. 2. The levels of serum chondroitin sulfate epitope 3B3 (A) 
and WF6 (B) and hyaluronan (C) in the non-hip dysplasia group.
This group was categorized into 5 different subgroup due to  body
weight such as group 1 (less than 10 kg, n = 15), group 2 (from 10
kg to less than 15 kg, n = 30), group 3 (from 15 kg to less than 20
kg, n = 28), group 4 (from 20 kg to less than 25 kg, n = 15) and 
group 5 (greater than or equal to 25 kg, n = 10). No significant 
difference (p ＞ 0.05) was observed among the subgroups.
lower when compared with that of the non-OA horses. 
Moreover, the level of CS epitope 3B3 rose not only in the 
early phase of OA, but also in young animals as compared 
with the mature animals [47]. It can be stated that the CS 
epitope 3B3 responds to the cartilage anabolism. Coincid-
ing with these previous results, the level of CS epitope 3B3 
in the HD dogs was lower than that in the non-HD dogs. 
This shows that the metabolism of articular cartilage in HD 
doesn’t involve the synthesis of new CS molecules. Hence, 
the cartilages become highly degraded and this then causes 
severe disease. 
  HA is one of the ECM molecules of the articular cartilage. 
Previous studies have shown that HA can be used as a 
biomarker in OA dogs [4,10,34] and rheumatoid disease 
[4,46]. Our study demonstrates for the first time the 
determination of the serum HA levels in HD dogs. We 
observed that the level of HA in the HD group was 45% 
lower than that in the non-HD group. This result is the same 
as the previous work on inflammatory joint disease: the HA 
concentration in the joint fluid and serum of animals with 
diseased joints has been reported to be lower than normal 
[14,35]. However, many studies have shown the 
relationship between the HA level in serum and liver 
disease [18,60] because the major site of metabolism for 
circulating HA is the liver. The lysosomes of the liver 
endothelial cells produce the enzymes hyaluronidase, 
β-glucuronidase and β-N-acetylglucosaminidase, and 
these are responsible for metabolizing HA to mono-
saccharides [57,58]. The level of serum HA was elevated 
when the function of the liver was interrupted by disease or 
chemicals [55]. To avoid these effects, we investigated the 
CBC and blood chemicals in both the HD and non-HD 
dogs, and abnormal liver signs were observed in both 
groups. The results indicated that the level of serum HA in 
our study is a direct effect of cartilage metabolism and is 
not a result of liver function.
  From the serological results, the WBC in the HD group 
was significantly higher than that in the non-HD group. 
Based on our knowledge, interleukin (IL-1) is mainly 
produced by cells of the macrophage lineage such as the 
synovial A-cell. Moreover, the IL-1 from synovial A-cells 
and other macrophage cells stimulates chondrocytes to 
produce IL-1 [7]. An increasing of IL-1 stimulates the 
production of collagenase, stromelysin and prostaglandin 
E2 by the chondrocytes. This mechanism induces 
inflammation to proceed in the dysplatic joint [8,24] and it 
increases the WBC. So far, this study supports those 
previous publications that were mention above. Our study 
found that the mean value of the WBC in the HD group was 
significantly higher than that in the non-HD group. 
However, the biological significance of the WBC in 
HD-dog needs future study to expand our understanding of 
the interaction between the WBC and HD-dogs.
  It is interesting to compare the results for the serum HA 
with the result for the CS epitopes (3B3 and WF6). The CS 
epitope 3B3 may provide a measure of the mobilization of 
the tissue proteoglycans that contain chondroitin 6-sulfate. Biomarkers for osteoarthritis in canine hip dysplasia    323
Fig. 3. The levels of serum chondroitin sulfate epitope 3B3 (A), WF6 (B) and hyaluronan (C) in the non-HD group. The animals of this
group were categorized into the male and female group. Data show the mean ± SD. No significant difference (p ＞ 0.05) was observed 
between the genders.
The 3B3 epitope is a 6-sulfated terminal disaccharide of CS 
[15]. The 3B3 assay that was developed in this study with 
using monoclonal antibody recognizes the unsaturated 
terminal 6-sulfateed disaccharide structure that remains 
attached to the protein after chondroitinase ABC digestion. 
As the aggrecan degradation products from cartilage were 
likely to be present in the serum and to be polyvalent, the 
detection with 3B3 epitope may selectively provide a 
measure of anabolism in the cartilaginous tissues. The 
level of native CS epitope detected by monoclonal 
antibody WF6 in the HD group was increased above the 
level found in the non-HD group. An increase in the WF6 
epitope may reflect a catabolic response and this may be 
helpful for making the diagnosis or predicting the 
prognosis of disease. 
  Moreover, this study shows the advantage of using these 
biomarkers. Body weight, which is known as a pre-
disposing cause of OA [59], is not affected by the level of 
these biomarkers. This means that the changes of the 
biomarkers’ levels in serum are dependent on the severity 
of disease. Also, a previous study from our group 
demonstrated that the levels of CS epitope WF6 and 3B3 
were not different between different body weight groups of 
horses [47]. This shows that the change of biomarker levels 
in the serum is directly related to the cartilage metabolism. 
However, the relationship between the severity of disease 
and the change of those biomarkers or other factors (such 
as the disease management and breed of animal) needs to 
be investigated for enlightening our understanding of the 
pathogenesis of the articular cartilage in HD disease. 
    In conclusion, our study raises important questions 
concerning the alterations in cartilage aggrecan metabolism 
in HD dogs. We have demonstrated the potential for using 
measurements of aggrecan epitopes and HA in the serum as 
indicators of disease activity. Indeed, the results of the 
present study suggest that several target biomarker 
molecules of cartilage metabolism have the potential to 
provide clinically useful indices of the effects of isolated 
joint injury, the progression of the joint changes and the 
response to therapy. The levels of the CS epitopes 3B3 and 
WF6 in serum were increased, while the HA levels show a 
decrease in hip dysplatic dogs. This information may prove 
useful for making the differential diagnosis and monitoring 
joint disease. 
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